



SAFETY DATA SHEET

Revision date: 29-Jul-2016

Version: 1.0

Page 1 of 8

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Desmopressin Acetate Injection USP (Hospira Inc.)

Trade Name: Desmopressin Acetate Injection, USP

Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company

275 North Field Drive

Lake Forest, Illinois 60045

1-800-879-3477

Hospira UK Limited

Horizon

Honey Lane

Hurley

Maidenhead, SL6 6RJ

United Kingdom

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

Label Elements

Signal Word: Not Classified

Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

No data available

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Desmopressin Acetate Trihydrate	62357-86-2	Not Listed	Not Listed	<0.001

SAFETY DATA SHEET

Material Name: Desmopressin Acetate Injection USP (Hospira Inc.)
Revision date: 29-Jul-2016

Page 2 of 8

Version: 1.0

3. COMPOSITION / INFORMATION ON INGREDIENTS

HYDROCHLORIC ACID	7647-01-0	231-595-7	Skin Corr.1B (H314) STOT SE 3 (H335)	**
-------------------	-----------	-----------	---	----

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Water for Injection	7732-18-5	231-791-2	Not Listed	*
SODIUM CHLORIDE	7647-14-5	231-598-3	Not Listed	*

Additional Information:

* Proprietary

** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact:

Rinse thoroughly with plenty of water, also under the eyelids. If irritation occurs or persists, get medical attention.

Skin Contact:

Wash off immediately with soap and plenty of water. If skin irritation persists, call a physician.

Ingestion:

Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation:

Move to fresh air If discomfort occurs, get medical attention.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of

For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Exposure:

Medical Conditions

None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician:

None

5. FIRE FIGHTING MEASURES

Extinguishing Media:

As for primary cause of fire.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion

Formation of toxic gases is possible during heating or fire.

Products:

Fire / Explosion Hazards:

Not applicable

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

SAFETY DATA SHEET

Material Name: Desmopressin Acetate Injection USP (Hospira Inc.)
Revision date: 29-Jul-2016

Page 3 of 8

Version: 1.0

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Restrict access to work area. Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Incompatible Materials: None known

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

SODIUM CHLORIDE

Latvia OEL - TWA	5 mg/m ³
Lithuania OEL - TWA	5 mg/m ³

HYDROCHLORIC ACID

ACGIH Ceiling Threshold Limit:	2 ppm
Australia PEAK	5 ppm
	7.5 mg/m ³
Austria OEL - MAKs	5 ppm
	8 mg/m ³
Belgium OEL - TWA	5 ppm
	8 mg/m ³
Bulgaria OEL - TWA	5 ppm
	8.0 mg/m ³
Cyprus OEL - TWA	5 ppm
	8 mg/m ³
Czech Republic OEL - TWA	8 mg/m ³
Estonia OEL - TWA	5 ppm
	8 mg/m ³
Germany - TRGS 900 - TWAs	2 ppm
	3 mg/m ³

SAFETY DATA SHEET

Material Name: Desmopressin Acetate Injection USP (Hospira Inc.)
Revision date: 29-Jul-2016

Page 4 of 8

Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Germany (DFG) - MAK	2 ppm 3.0 mg/m ³
Greece OEL - TWA	5 ppm 7 mg/m ³
Hungary OEL - TWA	8 mg/m ³
Ireland OEL - TWAs	5 ppm 8 mg/m ³
Italy OEL - TWA	5 ppm 8 mg/m ³
Japan - OELs - Ceilings	2 ppm 3.0 mg/m ³
Latvia OEL - TWA	5 ppm 8 mg/m ³
Lithuania OEL - TWA	5 ppm 8 mg/m ³
Luxembourg OEL - TWA	5 ppm 8 mg/m ³
Malta OEL - TWA	5 ppm 8 mg/m ³
Netherlands OEL - TWA	8 mg/m ³
Poland OEL - TWA	5 mg/m ³
Portugal OEL - TWA	5 ppm 8 mg/m ³
Romania OEL - TWA	5 ppm 8 mg/m ³
Slovakia OEL - TWA	5 ppm 8.0 mg/m ³
Slovenia OEL - TWA	5 ppm 8 mg/m ³
Spain OEL - TWA	5 ppm 7.6 mg/m ³
Switzerland OEL -TWAs	2 ppm 3.0 mg/m ³
Vietnam OEL - TWAs	5 mg/m ³

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Desmopressin Acetate Trihydrate

Pfizer Occupational Exposure OEB 5 (control exposure to <1ug/m³)
Band (OEB):

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section. It is recommended that all operations be fully enclosed and no air recirculated.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

SAFETY DATA SHEET

Material Name: Desmopressin Acetate Injection USP (Hospira Inc.)
Revision date: 29-Jul-2016

Page 5 of 8

Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Hands:	Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)
Eyes:	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)
Skin:	Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)
Respiratory protection:	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Liquid	Color:	Colorless
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solvent Solubility:	No data available		
Water Solubility:	Soluble		
pH:	3.5-6		
Melting/Freezing Point (°C):	No data available		
Boiling Point (°C):	No data available		
Partition Coefficient: (Method, pH, Endpoint, Value)			
Water for Injection			
No data available			
SODIUM CHLORIDE			
No data available			
HYDROCHLORIC ACID			
No data available			
Desmopressin Acetate Trihydrate			
No data available			
Decomposition Temperature (°C):	No data available.		
Evaporation Rate (Gram/s):	No data available		
Vapor Pressure (kPa):	No data available		
Vapor Density (g/ml):	No data available		
Relative Density:	No data available		
Viscosity:	No data available		
Flammability:			
Autoignition Temperature (Solid) (°C):	No data available		
Flammability (Solids):	No data available		
Flash Point (Liquid) (°C):	No data available		
Upper Explosive Limits (Liquid) (% by Vol.):	No data available		
Lower Explosive Limits (Liquid) (% by Vol.):	No data available		

10. STABILITY AND REACTIVITY

Reactivity:	No data available
Chemical Stability:	Stable under normal conditions of use.
Possibility of Hazardous Reactions	

SAFETY DATA SHEET

Material Name: Desmopressin Acetate Injection USP (Hospira Inc.)
Revision date: 29-Jul-2016

Page 6 of 8

Version: 1.0

10. STABILITY AND REACTIVITY

Oxidizing Properties: None
Conditions to Avoid: None known
Incompatible Materials: None known
Hazardous Decomposition Products: None known

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.
Known Clinical Effects: The most common adverse effects seen during clinical use of this drug include headache, nausea, decrease in blood pressure (hypotension), abdominal cramping, decreased sodium.

Acute Toxicity: (Species, Route, End Point, Dose)

SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³
Rat Oral LD 50 3g/kg
Mouse Oral LD 50 4g/kg
Rabbit Dermal LD 50 > 10g/kg

HYDROCHLORIC ACID

Rat Oral LD 50 238-277 mg/kg

Desmopressin Acetate Trihydrate

Rat Intravenous LD50 > 2 mg/kg
Mouse IV LD50 > 2mg/kg
Rabbit Intravenous LD50 > 50mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE

Skin Irritation Rabbit Mild
Eye Irritation Rabbit Mild

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Desmopressin Acetate Trihydrate

Embryo / Fetal Development Rat Subcutaneous 10 ug/kg/day NOAEL Not teratogenic
Embryo / Fetal Development Rabbit Subcutaneous 10 ug/kg/day NOAEL Not Teratogenic

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

HYDROCHLORIC ACID

IARC: Group 3 (Not Classifiable)

SAFETY DATA SHEET

Material Name: Desmopressin Acetate Injection USP (Hospira

Page 7 of 8

Inc.)

Revision date: 29-Jul-2016

Version: 1.0

12. ECOLOGICAL INFORMATION

Environmental Overview:	Environmental properties have not been investigated. Releases to the environment should be avoided.
Toxicity:	No data available
Persistence and Degradability:	No data available
Bio-accumulative Potential:	No data available
Mobility in Soil:	No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:	Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.
---------------------------------	---

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Desmopressin Acetate Trihydrate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Water for Injection

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed

SAFETY DATA SHEET

Material Name: Desmopressin Acetate Injection USP (Hospira

Page 8 of 8

Inc.)

Revision date: 29-Jul-2016

Version: 1.0

15. REGULATORY INFORMATION

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

SODIUM CHLORIDE

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-598-3

HYDROCHLORIC ACID

CERCLA/SARA 313 Emission reporting	1.0 %
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	5000 lb 2270 kg
CERCLA/SARA - Section 302 Extremely Hazardous TPQs	500 lb
CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs	5000 lb
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 5 Schedule 6
EU EINECS/ELINCS List	231-595-7

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage

Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Revision date: 29-Jul-2016
Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet